Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats

Journal of Anesthesia

Volumn 25, Issue 2, 2011, Pages 241-246

  Staals, Lonneke M ^a,b   Boer, Hans D De ^c   Egmond, Jan Van ^a   Hope, Frank ^d   Pol, Francien Van De ^a   Bom, Anton H ^d   Driessen, Jacques J ^a   Booij, Leo H D J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonism; Cat; Kidney failure; Neuromuscular block; Rocuronium; Sugammadex

Indexed keywords

CHLORALOSE; KETAMINE; MEDETOMIDINE; OXYGEN; PLACEBO; ROCURONIUM; SUGAMMADEX;

ACUTE KIDNEY FAILURE; AIR; ANESTHETIC RECOVERY; ANIMAL EXPERIMENT; ARTICLE; ARTIFICIAL VENTILATION; CAT; CONTROLLED STUDY; HEMODYNAMICS; INTUBATION; KIDNEY ARTERY STENOSIS; KIDNEY PERFUSION; MALE; MUSCLE TWITCH; NEUROMUSCULAR BLOCKING; NONHUMAN;

ANDROSTANOLS; ANIMALS; CATS; GAMMA-CYCLODEXTRINS; HEART RATE; MALE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; RENAL CIRCULATION;

EID: 79960027302     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-010-1090-3     Document Type: Article

References (18)

1. Hunter JM. New neuromuscular blocking drugs. N Engl J Med. 1995;332:1691-9.
2. Berg H, Roed J, Viby-Mogenson J, Mortenson CR, Engbaek J, Skovgaard LT, Krintel JJ. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41:1095-103.
3. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009;103:115-29.
4. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrinbased synthetic host. Angew Chem Int Ed. 2002;41:265-70. (Pubitemid 34126377)
5. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24:29-35.
6. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex; a dose-finding and safety study. Anesthesiology. 2006;104:667-74.
7. De Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107:239-44. (Pubitemid 47196486)
8. Gijsenbergh F, Ramael S, Houwing N, Van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695-703. (Pubitemid 41415517)
9. Proost JH, Eriksson LI, Mirakhur RK, Roest G, Wierda JMKH. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth. 2000;85:717-23.
10. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology. 2007;106:935-43. (Pubitemid 46684059)
11. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogenson J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51: 789-808. (Pubitemid 47063004)
12. Staals LM, Snoeck MMJ, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with endstage renal failure or normal renal function. Br J Anaesth. 2008;101:492-7.
13. Staals LM, Snoeck MMJ, Driessen JJ, Van Hamersvelt HW, Flockton EA, Van den Heuvel MW, Hunter JM. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010;104:31-9.
14. De Boer HD, Van Egmond J, Van de Pol F, Bom A, Booij LH. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology. 2006;104:718-23.
15. Khuenl-Brady K, Castagnoli KP, Canfell PC, Caldwell JE, Agoston S, Miller RD. The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology. 1990;72:669-74. (Pubitemid 20114714)
16. Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. Eur J Anaesthesiol. 2005;22:4-10. (Pubitemid 41320912)
17. Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth. 1993;71:222-6. (Pubitemid 23229381)
18. Kocabas S, Yedicocuklu D, Askar FZ. The neuromuscular effects of 0.6 mg kg-1 rocuronium in elderly and young adults with or without renal failure. Eur J Anaesthesiol. 2008;25:940-6.